MedPath

Evaluating the effect of tropical sildenafil gel on incidence and severity of Raynaud’s Phenomenon Attacks in patients with systemic sclerosis: A double blinded randomized clinical trial

Phase 3
Recruiting
Conditions
systemic sclerosis.
Systemic sclerosis [scleroderma]
Registration Number
IRCT20240203060886N1
Lead Sponsor
Shahre-kord University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
70
Inclusion Criteria

Age over 18 and under 75 years
Patients with systemic sclerosis diagnosed by ACR criteria or LeRoy ? Medsger
Willingness to participate in the clinical trial
Absence of MI, stroke or cardiac arrhythmia in recent 6 month
Skin involvement limited to fingers, hands, face, forearms and feet

Exclusion Criteria

History of CKD (Creatinine clearance under ?? ml/minute) or cirrhosis (Child-Pugh class C)
Overlap syndrome
Hypersnsitivity to topical sildenafil

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of pain. Timepoint: Measurement of pain severity before the intervention and 2 and 6 weeks after the intervention. Method of measurement: Visual Analogue Scale (VAS) Questionnaire.;Quality of life. Timepoint: Measuring different aspects of quality of life before the intervention and 2 and 6 weeks after the intervention. Method of measurement: The World Health Organization Quality of Life Brief Version (WHOQOL-BREF).;Capiloroscopy of the nail bed of patients. Timepoint: before the intervention and 2 and 6 weeks after the intervention. Method of measurement: nailfold capiloroscope.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath